1 completed, 1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Catherine Shu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Durvalumab, Tremelimumab - Nonsmall Cell Lung Cancer | Phase 2 | Withdrawn | Catherine Shu | 2022-12-01 | 2023-06-06 | |
| SGI-110 Plus Durvalumab/Tremelimumab in SCLC Durvalumab, Tremelimumab, SGI-110 - Extensive-stage Small Cell Lung Cancer | Phase 1 | Completed | Catherine Shu | 2 | 2017-12-15 | 2018-12-10 |
Carcinoma, Non-Small-Cell Lung (1) · Small Cell Lung Carcinoma (1)
durvalumab (2) · tremelimumab (2) · guadecitabine (1)
United States (1)